Correction to: J Nanobiotechnol (2020) 18:66 https://doi.org/10.1186/s12951-020-00622-5

Following publication of the original article [1], the authors reported that Fig. 2 was not updated during the production process.

The updated Fig. 2 is provided below and the original article [1] has been corrected.

Fig. 2
figure 2

M2D-Exos induce osteoblast activity and matrix mineralization. a Osteogenic genes were upregulated in M2D-Exos-treated BMSCs measured by western blotting analysis; b The relative intensity of western blotting analysis; c Overexpression of the four osteognic genes can be detected in M2D-Exos groups measured by qRT-PCR analysis; d Alizarin red-mediated calcium staining in BMSCs following treated by PBS (control group), M1D-Exos, and M2D-Exos for 21 days. Scale bar = 10 mm; e ALP staining in BMSCs following treated by PBS (control group), M1D-Exos, and M2D-Exos for 14 days. Scale bar = 10 mm; f, g The statistical data of Alizarin red-mediated calcium staining and ALP staining. Data are mean ± SD of triplicate experiments. *p < 0.001, **p < 0.01, ***p < 0.001